An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

Summary

This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following prior treatment (biochemical recurrence) but who were prostate specific membrane antigen negative on their most recent PET scan. Contrast agents like rhPSMA-7.3 (also called POSLUMA) circulate in the blood until they find their intended target. Once they are taken up by the target tumor cells, they can be visualized using PET/CT cameras.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Biochemically Recurrent Prostate Carcinoma
• Prostate Adenocarcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Early Phase 1

Ages

Any age

Sex

Male

Healthy volunteers

Not accepted

Sponsor

Northwestern University

Last updated on ClinicalTrials.gov

July 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites